196 related articles for article (PubMed ID: 35767251)
21. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
Korotych O; Achar J; Gurbanova E; Hovhannesyan A; Lomtadze N; Ciobanu A; Skrahina A; Dravniece G; Kuksa L; Rich M; Khachatryan N; Germanovych M; Kadyrov A; Terleieva I; Akhundova I; Adenov M; Durdyeva M; Kiria N; Parpieva N; Yatskevich N; Jumayev R; Nurov R; Diktanas S; Vilc V; Migliori GB; Yedilbayev A
Lancet Infect Dis; 2024 Jun; ():. PubMed ID: 38880112
[TBL] [Abstract][Full Text] [Related]
22. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review.
Putra ON; Yulistiani Y; Soedarsono S; Subay S
Int J Mycobacteriol; 2023; 12(1):1-9. PubMed ID: 36926755
[TBL] [Abstract][Full Text] [Related]
23. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
[TBL] [Abstract][Full Text] [Related]
24. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
Esmail A; Oelofse S; Lombard C; Perumal R; Mbuthini L; Goolam Mahomed A; Variava E; Black J; Oluboyo P; Gwentshu N; Ngam E; Ackerman T; Marais L; Mottay L; Meier S; Pooran A; Tomasicchio M; Te Riele J; Derendinger B; Ndjeka N; Maartens G; Warren R; Martinson N; Dheda K
Am J Respir Crit Care Med; 2022 May; 205(10):1214-1227. PubMed ID: 35175905
[No Abstract] [Full Text] [Related]
25. Effectiveness of a bedaquiline, linezolid, clofazimine "core" for multidrug-resistant tuberculosis.
Zeng C; Hernán MA; Trevisi L; Sauer S; Mitnick CD; Hewison C; Bastard M; Khan P; Seung KJ; Rich ML; Law S; Kikvidze M; Kirakosyan O; Miankou A; Thit P; Mamsa S; Janmohamed A; Melikyan N; Ahmed S; Vargas D; Binegdie AB; Temirova K; Oyewusi L; Philippe K; Vilbrun SC; Khan U; Huerga H; Franke MF;
medRxiv; 2024 Jan; ():. PubMed ID: 38293100
[TBL] [Abstract][Full Text] [Related]
26. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
[TBL] [Abstract][Full Text] [Related]
27. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis.
Fu L; Weng T; Sun F; Zhang P; Li H; Li Y; Yang Q; Cai Y; Zhang X; Liang H; Chen X; Wang Z; Liu L; Zhang W; Deng G
Int J Infect Dis; 2021 Oct; 111():138-147. PubMed ID: 34454119
[TBL] [Abstract][Full Text] [Related]
28. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
[TBL] [Abstract][Full Text] [Related]
29. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
30. Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study.
Fu L; Zhang X; Xiong J; Sun F; Weng T; Li Y; Zhang P; Li H; Yang Q; Cai Y; Liang H; Chen Q; Wang Z; Liu L; Chen X; Zhang W; Deng G
Int J Infect Dis; 2023 Oct; 135():101-108. PubMed ID: 37567554
[TBL] [Abstract][Full Text] [Related]
31. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
Van Deun A; Decroo T; Tahseen S; Trébucq A; Schwoebel V; Ortuno-Gutierrez N; de Jong BC; Rieder HL; Piubello A; Chiang CY
Int J Antimicrob Agents; 2020 Jan; 55(1):105822. PubMed ID: 31626907
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.
Pecora F; Dal Canto G; Veronese P; Esposito S
Microorganisms; 2021 May; 9(5):. PubMed ID: 34067732
[TBL] [Abstract][Full Text] [Related]
33. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective
Kaniga K; Hasan R; Jou R; Vasiliauskienė E; Chuchottaworn C; Ismail N; Metchock B; Miliauskas S; Viet Nhung N; Rodrigues C; Shin S; Simsek H; Smithtikarn S; Ngoc ALT; Boonyasopun J; Kazi M; Kim S; Kamolwat P; Musteikiene G; Sacopon CA; Tahseen S; Vasiliauskaitė L; Wu MH; Vally Omar S
J Clin Microbiol; 2022 Jan; 60(1):e0291920. PubMed ID: 34705538
[TBL] [Abstract][Full Text] [Related]
34. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
[TBL] [Abstract][Full Text] [Related]
35. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
Roelens M; Battista Migliori G; Rozanova L; Estill J; Campbell JR; Cegielski JP; Tiberi S; Palmero D; Fox GJ; Guglielmetti L; Sotgiu G; Brust JCM; Bang D; Lienhardt C; Lange C; Menzies D; Keiser O; Raviglione M
Am J Respir Crit Care Med; 2021 Sep; 204(6):713-722. PubMed ID: 34107231
[No Abstract] [Full Text] [Related]
36. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD
Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644
[No Abstract] [Full Text] [Related]
37. Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18.
Auchynka V; Kumar AMV; Hurevich H; Sereda Y; Solodovnikova V; Katovich D; Setkina S; Yedilbayev A; Skrahin A; Skrahina A
Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470081
[TBL] [Abstract][Full Text] [Related]
38. Treatment outcomes of pre- and extensively drug-resistant tuberculosis in Johannesburg, South Africa.
Nkurunziza J; Karstaedt AS; Louw R; Padanilam X
Int J Tuberc Lung Dis; 2018 Dec; 22(12):1469-1474. PubMed ID: 30606319
[TBL] [Abstract][Full Text] [Related]
39. Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.
Diriba G; Alemu A; Yenew B; Tola HH; Gamtesa DF; Mollalign H; Eshetu K; Moga S; Abdella S; Tollera G; Kebede A; Dangisso MH
Int J Infect Dis; 2023 Jul; 132():50-63. PubMed ID: 37072053
[TBL] [Abstract][Full Text] [Related]
40. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
